This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in the Cards for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for Humira in the United States to boost AbbVie's (ABBV) first-quarter sales.
Pharma Stock Roundup: JNJ's Q1 Earnings & Sales Beat, RHHBY Sales, & Other Updates
by Kinjel Shah
J&J (JNJ) beats Q1 estimates for earnings and sales. Roche (RHHBY) announces Q1 sales numbers.
Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Whether Amgen's (AMGN) sales recovery from the COVID-19 effect continued in the first quarter is what remains to be seen when the company reports.
SAP SE (SAP) Q1 Earnings Improve on a Year-Over-Year Basis
by Zacks Equity Research
SAP SE (SAP) announces upbeat first-quarter 2021 results driven by strength in cloud business.
What's in the Cards for Eli Lilly (LLY) This Earnings Season?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) first-quarter sales.
Astrazeneca (AZN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $52.27, marking a +1.24% move from the previous day.
Top Analyst Reports for Walmart, Comcast & Broadcom
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), Comcast (CMCSA), and Broadcom (AVGO).
Pfizer (PFE)/ BioNTech to Supply Extra Comirnaty Doses to EU
by Zacks Equity Research
The European Commission exercises its option to purchase an additional 100 million doses of Pfizer (PFE)/ BioNTech's COVID-19 vaccine, Comirnaty, for EU member states.
AstraZeneca (AZN) Gets FTC Clearance for Alexion Acquisition
by Zacks Equity Research
AstraZeneca (AZN) obtains U.S. Federal Trade Commission's permission for the Alexion acquisition. The deal is expected to close in the third quarter of 2021.
Biogen (BIIB) to Report Q1 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports first-quarter earnings.
Pharma Stock Roundup: JNJ's COVID-19 Vaccine Woes, MRK Ends COVID-19 Drug Development
by Kinjel Shah
FDA & CDC temporarily halt J&J's (JNJ) COVID-19 vaccine use. Merck (MRK) ends development of COVID-19 drug.
Will J&J (JNJ) Kickstart Pharma Q1 Earnings With a Beat?
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market while moderate procedural disruption might have hurt the Medical Devices segment in the first quarter.
Which Vaccine Maker Will Win the Fight Against COVID-19?
by Kinjel Shah
A comparison between COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX), Moderna's (MRNA), AstraZeneca (AZN) and J&J (JNJ) is inevitable.
J&J (JNJ) COVID-19 Jab to be Paused on FDA/CDC Recommendation
by Zacks Equity Research
FDA/CDC said that rare and severe blood clots accompanied by low levels of blood platelets have been identified in six individuals who received J&J's (JNJ) COVID-19 vaccine.
S&P 500 Hits Another New All-Time High
by Mark Vickery
The index's totals weren't super-noteworthy in the daily performance, +0.33%, but this April has seen multiple new highs four of the past six sessions.
AstraZeneca (AZN) Farxiga COVID-19 Study Fails to Meet Goal
by Zacks Equity Research
AstraZeneca's (AZN) phase III study on Farxiga in hospitalized COVID-19 patients with pre-existing health conditions fails to show statistical significance for the primary endpoint
Pharma Stock Roundup: FDA Decision Delays for PFE, LLY, ABBV, AZN Vaccine Woes
by Kinjel Shah
FDA delays decision on Pfizer (PFE), AbbVie (ABBV) and Lilly's (LLY) filings for JAK inhibitor candidates. AstraZeneca's (AZN) COVID-19 vaccine troubles continue.
Top COVID-19 Vaccine Stories of March Put Biotech ETFs in Focus
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.
Novartis (NVS) Teams Up With Artios for Radioligand Therapies
by Zacks Equity Research
Novartis (NVS) enters a three-year collaboration with Artios to strengthen its radiogland therapies pipeline.
Gilead (GILD) Gets Full Approval for Breast Cancer Drug Trodelvy
by Zacks Equity Research
Gilead (GILD) obtains full approval for its breast cancer drug, Trodelvy, in the United States for metastatic triple-negative breast cancer.
AstraZeneca (AZN) COVID-19 Jab May Have Link to Rare Blood Clots
by Zacks Equity Research
European regulators find a possible link between AstraZeneca's (AZN) COVID-19 vaccine and rare blood clot events.
AstraZeneca (AZN) COVID-19 Vaccine Dosing Halted in Kids Study
by Zacks Equity Research
Oxford University pauses dosing in AstraZeneca's (AZN) COVID-19 vaccine study in children until U.K. regulator completes review of fresh rare blood clot events.
Emergent (EBS) Gets Extra $23M for COVID-19 Vaccine Production
by Zacks Equity Research
Emergent (EBS) receives additional $23 million from BARDA to support further expansion of manufacturing capacity for Johnson & Johnson's COVID-19 vaccine.
J&J (JNJ) Gets Full Charge of Emergent COVID-19 Vaccine Plant
by Zacks Equity Research
The U.S. government places J&J (JNJ) in charge of Emergent's Baltimore factory. The facility will cease production of AstraZeneca shots.
Will ETFs Gain on AstraZeneca's Latest Covid-19 Vaccine Update?
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence thanks to multiple mutants.